Reaction
Gastroenteropancreatic Neuroendocrine Tumour Disease reporting signals
As of the last recalculation, Gastroenteropancreatic Neuroendocrine Tumour Disease appears in 111 FAERS reports alongside 3 co-occurring drug terms. The strongest observed disproportionality signal is OCTREOTIDE ACETATE (PRR 1,413.5).
Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.
| Drug | Co-reports | PRR | ROR |
|---|---|---|---|
| Octreotide Acetate | 75 | 1,413.5 | 1,417.0 |
| Granisetron | 5 | 93.6 | 93.6 |
| Temozolomide | 7 | 66.4 | 66.4 |